Cargando…
Methotrexate (MTX) inhibition of cytokine production: relationship with clinical outcome and genetic polymorphisms
Autores principales: | Sabina, P, Balsa, A, Miranda, ME, Martin, J, Pascual, M, Martín Mola, E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833683/ http://dx.doi.org/10.1186/ar989 |
Ejemplares similares
-
Crosstalk between synovial fibroblasts and T lymphocytes in rheumatoid arthritis: effect of methotrexate
por: Miranda, E, et al.
Publicado: (2003) -
How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
por: Taylor, Peter. C., et al.
Publicado: (2019) -
Differential effects of leflunomide and methotrexate on cytokine production in RA
por: Kraan, MC, et al.
Publicado: (2003) -
Expression of TRAIL-R2 (DR5) on fibroblasts from synovial fluid of rheumatoid arthritis
por: Miranda, E, et al.
Publicado: (2004) -
Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)